In addition, the co-stimulatory molecules expressed in the tumor samples with the two mutations were also different (16).Combined with our study, we speculate that the tumor microenvironment of EGFR20ins may be more suitable for immunotherapy and chemotherapy, while the tumor microenvironment of HER2-20ins perhaps benefit more from anti-vascular therapy, which requires more clinical data and basic research to verify. The gene discussed is ERBB2; the disease is neoplasm.